Results: It was observed that E2F1 levels were significantly elevated in the MS group compared to controls (p = 0.011). A subgroup analysis revealed higher E2F1 levels in relapsing-remitting MS (RRMS) than in progressive forms (SPMS and PPMS) (p = 0.024). Here, E2F1 is linked to myeloid sarcoma.